

Richard J Santen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5609430/richard-j-santen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

8,802
citations

56
h-index

92
g-index

137
ext. papers

9,553
ext. citations

6.8
avg. IF

5.81
L-index

#	Paper	IF	Citations
128	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3975-4011	5.6	434
127	Postmenopausal hormone therapy: an Endocrine Society scientific statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, s1-s66	5.6	429
126	Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. <i>Molecular Endocrinology</i> , 2002 , 16, 116-27		338
125	Endocrine treatment of breast cancer in women. <i>Endocrine Reviews</i> , 1990 , 11, 221-65	27.2	330
124	The role of mitogen-activated protein (MAP) kinase in breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 80, 239-56	5.1	312
123	Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. <i>Prostate</i> , 1987 , 11, 229-42	4.2	292
122	The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 2076-81	11.5	290
121	Atypical hyperplasia of the breast--risk assessment and management options. <i>New England Journal of Medicine</i> , 2015 , 372, 78-89	59.2	207
120	Benign breast disorders. <i>New England Journal of Medicine</i> , 2005 , 353, 275-85	59.2	202
119	A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. <i>New England Journal of Medicine</i> , 1981 , 305, 545-51	59.2	178
118	Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. <i>Cancer Research</i> , 2007 , 67, 1352-60	10.1	159
117	Standardization of steroid hormone assays: why, how, and when?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1713-9	4	158
116	Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. <i>Cancer Prevention Research</i> , 2014 , 7, 211-7	3.2	150
115	Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. <i>Steroids</i> , 2013 , 78, 161-70	2.8	146
114	Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. <i>Endocrinology</i> , 2000 , 141, 396-405	4.8	145
113	Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. <i>Annals of Internal Medicine</i> , 1982 , 96, 94-101	8	144
112	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87	5.7	141

111	Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. <i>Endocrinology</i> , 1998 , 139, 4164-74	4.8	136
110	Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2104-9	5.6	118
109	Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. <i>Steroids</i> , 2007 , 72, 666-71	2.8	117
108	Aromatase activity in primary and metastatic human breast cancer. <i>Cancer</i> , 1987 , 59, 779-82	6.4	117
107	Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. <i>Endocrinology</i> , 2007 , 148, 4091-101	4.8	113
106	Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. <i>Prostate</i> , 1985 , 7, 41-51	4.2	109
105	Resistance of the ovary to blockade of aromatization with aminoglutethimide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980 , 51, 473-7	5.6	107
104	An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. <i>New England Journal of Medicine</i> , 1991 , 324, 317-22	59.2	102
103	Estrogen metabolites and breast cancer. <i>Steroids</i> , 2015 , 99, 61-6	2.8	99
102	Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 126-37	6.5	93
101	Treatment of urogenital atrophy with low-dose estradiol: preliminary results. <i>Menopause</i> , 2002 , 9, 179-87.5	8.5	88
100	Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. <i>Cancer</i> , 1995 , 75, 2132-8	6.4	87
99	Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 294, 926-33	3.4	86
98	Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. <i>Endocrinology</i> , 2002 , 143, 3221-9	4.8	79
97	Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2000 , 62, 167-75	4.4	79
96	Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 115-25	5.1	79
95	Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. <i>Cancer</i> , 1984 , 53, 1447-50	6.4	79
94	Treatment of breast cancer with gonadotropin-releasing hormone. <i>Endocrine Reviews</i> , 1986 , 7, 89-94	27.2	78

93	Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. <i>International Journal of Cancer</i> , 2010 , 127, 1748-57	7.5	77
92	Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 102-10	5.1	76
91	Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 86, 265-74	5.1	73
90	Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. <i>Cancer</i> , 1977 , 39, 2948-58	6.4	73
89	Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. <i>Steroids</i> , 2009 , 74, 586-94	2.8	71
88	Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010 , 118, 219-30	5.1	70
87	Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 200-8	5.6	69
86	Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 155-65	5.1	69
85	Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma. <i>Steroids</i> , 1982 , 39, 497-507	2.8	69
84	Progression of Metabolic Syndrome Severity During the Menopausal Transition. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	69
83	The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 44, 687-91	5.1	68
82	Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1155, 132-40	6.5	67
81	Inhibition of aromatase: insights from recent studies. <i>Steroids</i> , 2003 , 68, 559-67	2.8	67
80	Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 704-11	2.9	65
79	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3647-3661	5.6	62
78	Pharmacokinetics and pharmacodynamics of oral and transdermal 17 β -estradiol in girls with Turner syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3502-10	5.6	61
77	Adrenal suppression with aminoglutethimide. I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977 , 45, 469-79	5.6	61
76	A phase I trial of CGS 16949A. A new aromatase inhibitor. <i>Cancer</i> , 1990 , 65, 1279-85	6.4	60

75	Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13 Suppl 1, S3-13	5.7	59
74	Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 337S-45S	12.9	56
73	Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. <i>Journal of Urology</i> , 1976 , 115, 170-4	2.5	55
72	Celebrating 75 years of oestradiol. <i>Journal of Molecular Endocrinology</i> , 2015 , 55, T1-20	4.5	52
71	Estrogen stimulation of cell migration involves multiple signaling pathway interactions. <i>Endocrinology</i> , 2010 , 151, 5146-56	4.8	49
70	Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. <i>Molecular Endocrinology</i> , 2005 , 19, 175-83		48
69	To block estrogen synthesis or action: that is the question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3007-12	5.6	48
68	Long-term exposure to tamoxifen induces hypersensitivity to estradiol. <i>Clinical Cancer Research</i> , 2004 , 10, 1530-4	12.9	47
67	Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 630, 19-34	3.6	47
66	Aromatase immunoreactivity is increased in mammographically dense regions of the breast. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 243-52	4.4	45
65	Risk of breast cancer with progestins: critical assessment of current data. <i>Steroids</i> , 2003 , 68, 953-64	2.8	45
64	Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. <i>Steroids</i> , 2008 , 73, 1318-21	2.8	42
63	The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. <i>Cancer</i> , 1980 , 46, 1066-74	6.4	42
62	Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1790-1803	5.6	41
61	Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 99-106	5.6	40
60	Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1038-48	4	38
59	Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. <i>Endocrinology</i> , 2012 , 153, 5706-15	4.8	37
58	Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977 , 45, 739-46	5.6	37

57	Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 109-17	4.4	35
56	Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1407-13	5.6	35
55	Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo		34
54	Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro. <i>Endocrinology</i> , 2013 , 154, 656-65	4.8	33
53	Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. <i>Cancer</i> , 2001 , 92, 2095-101	6.4	33
52	Menopausal hormone therapy and breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 142, 52-61	5.1	31
51	Estrogens and Their Genotoxic Metabolites Are Increased in Obese Prepubertal Girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2322-8	5.6	30
50	Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. <i>Cancer Research</i> , 2007 , 67, 5717-26	10.1	28
49	Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. <i>International Journal of Cancer</i> , 2005 , 117, 746-54	7.5	27
48	Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. <i>Endocrinology</i> , 2009 , 150, 2036-45	4.8	26
47	Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinoma in vivo in the rat. <i>International Journal of Cancer</i> , 1990 , 46, 73-8	7.5	26
46	Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1970 , 31, 153-61	5.6	26
45	Regulated CYP19 aromatase transcription in breast stromal fibroblasts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 837-46	5.6	25
44	Effects of menopausal hormonal therapy on occult breast tumors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013 , 137, 150-6	5.1	22
43	Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 733-47	5.6	21
42	Systemic estradiol levels with low-dose vaginal estrogens. <i>Menopause</i> , 2020 , 27, 361-370	2.5	19
41	Occult breast tumor reservoir: biological properties and clinical significance. <i>Hormones and Cancer</i> , 2013 , 4, 195-207	5	18
40	Prolonged negative feedback suppression after estradiol administration: proposed mechanism of eugonadal secondary amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1978 , 47, 1220-9	5.6	18

39	Competency in menopause management: whither goest the internist?. <i>Journal of Women's Health</i> , 2014 , 23, 281-5	3	17
38	The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. <i>Prostate</i> , 2004 , 58, 325-34	4.2	17
37	The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. <i>Obstetrical and Gynecological Survey</i> , 1998 , 53, S1-83	2.4	17
36	Adenosine monophosphate activated protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-term estrogen deprived breast cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 821-30	5.4	16
35	Relative versus attributable risk of breast cancer from estrogen replacement therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1875-81	5.6	16
34	TMS, a chemically modified herbal derivative of resveratrol, induces cell death by targeting Bax. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 265-77	4.4	15
33	Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 105, 106-14	5.1	15
32	Animal model of isolated gonadotropin deficiency. I. Hormonal responses to LHRH immunoneutralization. <i>Journal of Andrology</i> , 1983 , 4, 233-9		15
31	History of Estrogen: Its Purification, Structure, Synthesis, Biologic Actions, and Clinical Implications. <i>Endocrinology</i> , 2019 , 160, 605-625	4.8	14
30	Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 779-89	4.4	12
29	Animal model of isolated gonadotropin deficiency. II. Morphologic responses to LHRH immunoneutralization. <i>Journal of Andrology</i> , 1983 , 4, 240-7		12
28	Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3630-3639	5.6	12
27	The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 44, 683-5	5.1	11
26	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	10
25	Ablative procedures in patients with metastatic breast carcinoma. <i>Cancer</i> , 1984 , 53, 762-5	6.4	10
24	Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study. <i>Climacteric</i> , 2019 , 22, 3-12	3.1	10
23	Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. <i>Clinical Endocrinology</i> , 2019 , 90, 155-161	3.4	9
22	Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. <i>Menopause</i> , 2017 , 24, 589-595	2.5	8

21	Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. <i>International Journal of Cancer</i> , 2018 , 143, 1259-1268	7.5	8
20	Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. <i>Breast Cancer Research</i> , 2014 , 16, 212	8.3	8
19	Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 343-51	4.4	8
18	Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. <i>Anti-Cancer Drugs</i> , 2006 , 17, 33-40	2.4	8
17	Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 170, 61-64	5.1	7
16	3. Mechanisms Relating Estrogens to Breast Cancer. <i>Translational Endocrinology & Metabolism</i> , 2012 , 75-93		7
15	Assessing individual risk for breast cancer: role of oestrogens and androgens. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S10	8.3	6
14	Recovery of hypothalamic-pituitary-adrenal function after long term suppression by aminoglutethimide and hydrocortisone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981 , 53, 879-82	5.6	5
13	Career Advancement: Meeting the Challenges Confronting the Next Generation of Endocrinologists and Endocrine Researchers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4512-4520	5.6	4
12	Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. <i>Menopause</i> , 2020 , 27, 614-624	2.5	4
11	Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells. <i>Breast Cancer: Basic and Clinical Research</i> , 2019 , 13, 1178223419844198	2.2	3
10	Aromatase inhibitors in breast cancer 2002 , 75-106		3
9	Meeting summary: Workshop conference on endocrine therapy of advanced prostate cancer, Airline house, November 3-4, 1996. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1997 , 3, 31-8	2.8	2
8	Novel methods of oestrogen deprivation for treatment of breast diseases. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989 , 95, 255-269		2
7	The oestrogen paradox: a hypothesis. <i>Endokrynologia Polska</i> , 2007 , 58, 222-7	1.1	2
6	Approach to Managing a Postmenopausal Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	1
5	Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. <i>Journal of Experimental Therapeutics and Oncology</i> , 2013 , 10, 169-79	0.8	0
4	Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019 , 7, 2324709619841414	1.2	

3 Hormone Responsive Cancers **2014**, 651-698.e14

2 Estrogen Replacement in Turner Syndrome **2020**, 93-122

1 WITHDRAWN - Administrative Duplicate Publication: Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. *Post Reproductive Health*, **2021**, 27, NP2-NP10

1.2